Literature DB >> 12643168

The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond.

Kambiz Kalantarinia1, Helmy M Siragy.   

Abstract

Affecting over 16 million individuals, diabetes mellitus is among the leading causes of mortality in the United States. Hypertension is a common finding among diabetic patients and increases their morbidity and mortality. Control of blood pressure in this population has been shown to improve outcomes. Recent randomized trials have proven the benefit of lower blood pressure goals in the treatment of hypertensive patients as compared with nondiabetic patients. Randomized controlled trials have also demonstrated that the selection of the antihypertensive agent used to treat hypertension in diabetic patients is as important as the reduction of blood pressure levels to the recommended levels. In this article, we first focus on the importance of the renin angiotensin system in the development of diabetic complications, and then we review the results of the recent studies that have had a major impact on the treatment of hypertension in diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12643168     DOI: 10.1007/s11892-002-0107-1

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  74 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Candesartan inhibits carotid intimal thickening and ameliorates insulin resistance in balloon-injured diabetic rats.

Authors:  M Igarashi; A Hirata; H Yamaguchi; H Tsuchiya; H Ohnuma; M Tominaga; M Daimon; T Kato
Journal:  Hypertension       Date:  2001-12-01       Impact factor: 10.190

3.  Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus.

Authors:  J C Chan; J A Critchley; B Tomlinson; T Y Chan; C S Cockram
Journal:  Am J Nephrol       Date:  1997       Impact factor: 3.754

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

6.  Activation of AT(2) receptors by endogenous angiotensin II is involved in flow-induced dilation in rat resistance arteries.

Authors:  K Matrougui; L Loufrani; C Heymes; B I Lévy; D Henrion
Journal:  Hypertension       Date:  1999-10       Impact factor: 10.190

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients.

Authors:  R Fogari; A Zoppi; P Lazzari; P Preti; A Mugellini; L Corradi; P Lusardi
Journal:  J Cardiovasc Pharmacol       Date:  1998-10       Impact factor: 3.105

9.  Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.

Authors:  M Ravid; R Lang; R Rachmani; M Lishner
Journal:  Arch Intern Med       Date:  1996-02-12

10.  Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.

Authors:  G L Bakris; M R Weir; V DeQuattro; F G McMahon
Journal:  Kidney Int       Date:  1998-10       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.